Literature DB >> 12909240

The epidermal growth factor receptor mediates radioresistance.

Ke Liang1, K Kian Ang, Luka Milas, Nancy Hunter, Zhen Fan.   

Abstract

PURPOSE: The epidermal growth factor (EGF) receptor is frequently overexpressed in malignant tumors, and its level is correlated with increased cellular resistance to ionizing radiation. However, no precedent studies have investigated whether expression of EGF receptor would by itself confer on cancer cells resistance to radiation. The current study is aimed to address this question. METHODS AND MATERIALS: A full-length human EGF receptor expression vector was transfected into the OCA-I murine ovarian carcinoma cells for stable clones expressing various levels of EGF receptors. Apoptosis and cell clonogenic survival assays were used to evaluate the sensitivity of the resulting cell clones to ionizing radiation.
RESULTS: OCA-I cell clones expressing various levels of EGF receptor (OCA-I EGFR) were obtained. These clones showed an EGF receptor level-dependent increase in resistance to ionizing radiation, measured by apoptosis and cell clonogenic survival assays. Compared with the results for parental OCA-I and control vector-transfected OCA-I cells at the 10% cell survival level, the radioresistance was increased by a factor of 1.60 for EGFR-C5 (high level of EGF receptor expression), 1.37 for EGFR-C3 (intermediate level of EGF receptor expression), and 1.28 for EGFR-C1 (low level of EGF receptor expression). Treatment of the OCA-I EGF receptor transfectants with the anti-EGF receptor monoclonal antibody C225 downregulated the levels of EGF receptor, reduced the phosphorylation levels of EGF receptor downstream substrates (such as Akt and MAPK), and reversed the cellular radioresistance.
CONCLUSION: Our results demonstrate that overexpression of the EGF receptor conferred cellular resistance to ionizing radiation. The EGF receptor is thus a valid target for potential radiosensitization.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12909240     DOI: 10.1016/s0360-3016(03)00511-x

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  92 in total

1.  Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC.

Authors:  Raymond H Mak; Elizabeth Doran; Alona Muzikansky; Josephine Kang; Joel W Neal; Elizabeth H Baldini; Noah C Choi; Henning Willers; David M Jackman; Lecia V Sequist
Journal:  Oncologist       Date:  2011-05-31

Review 2.  Targeting angiogenesis in gynecologic cancers.

Authors:  Behrouz Zand; Robert L Coleman; Anil K Sood
Journal:  Hematol Oncol Clin North Am       Date:  2012-06       Impact factor: 3.722

Review 3.  Non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases: role of tyrosine kinase inhibitors (TKIs) and evidence in favor or against their use with concurrent cranial radiotherapy.

Authors:  Panagiota Economopoulou; Giannis Mountzios
Journal:  Transl Lung Cancer Res       Date:  2016-12

Review 4.  Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer.

Authors:  Juliette Thariat; Luka Milas; K Kian Ang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-15       Impact factor: 7.038

5.  IFHNOS Global Continuing Education Program. Current concepts in head & neck surgery and oncology 2008.

Authors: 
Journal:  Acta Otorhinolaryngol Ital       Date:  2008-08       Impact factor: 2.124

Review 6.  New Therapies in Head and Neck Cancer.

Authors:  Rodell T Santuray; Daniel E Johnson; Jennifer R Grandis
Journal:  Trends Cancer       Date:  2018-04-19

Review 7.  Molecular Biology: Are We Getting Any Closer to Providing Clinically Useful Information?

Authors:  Georgios Karagkounis; Matthew F Kalady
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

8.  Constitutively active Harvey Ras confers resistance to epidermal growth factor receptor-targeted therapy with cetuximab and gefitinib.

Authors:  Rodney B Luwor; Yang Lu; Xinqun Li; Ke Liang; Zhen Fan
Journal:  Cancer Lett       Date:  2011-03-15       Impact factor: 8.679

Review 9.  Rectal cancer treatment: improving the picture.

Authors:  Juan A Diaz-Gonzalez; Leire Arbea; Javier Aristu
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

10.  [Prognostic significance of changes of tumor epidermal growth factor receptor expression after neoadjuvant chemoradiation in patients with rectal adenocarcinoma].

Authors:  J Dvorak; V Sitorova; A Ryska; I Sirak; I Richter; J Hatlova; A Ferko; B Melichar; J Petera
Journal:  Strahlenther Onkol       Date:  2012-08-01       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.